Atika Capital Management LLC Invests $1.53 Million in Xenon Pharmaceuticals Inc. $XENE

Atika Capital Management LLC acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 38,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,526,000.

A number of other large investors have also recently made changes to their positions in XENE. Holocene Advisors LP bought a new stake in Xenon Pharmaceuticals during the second quarter worth approximately $56,637,000. Geode Capital Management LLC lifted its stake in shares of Xenon Pharmaceuticals by 1,294.2% in the 2nd quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after purchasing an additional 900,746 shares during the last quarter. Braidwell LP boosted its holdings in shares of Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after purchasing an additional 895,154 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after purchasing an additional 700,000 shares during the period. Finally, Commodore Capital LP increased its position in shares of Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after purchasing an additional 700,000 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday. HC Wainwright increased their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush raised their target price on shares of Xenon Pharmaceuticals from $47.00 to $64.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $71.94.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE opened at $59.04 on Thursday. The firm has a 50-day simple moving average of $43.23 and a 200-day simple moving average of $41.69. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $63.95. The firm has a market cap of $4.91 billion, a P/E ratio of -13.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the company posted ($0.84) EPS. On average, research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 11,269 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $677,379.59. Following the sale, the chief executive officer owned 14,731 shares of the company’s stock, valued at approximately $885,480.41. This trade represents a 43.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $166,564.81. Following the completion of the transaction, the insider owned 4,729 shares in the company, valued at $284,260.19. This represents a 36.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 326,647 shares of company stock worth $19,066,951 over the last 90 days. Company insiders own 4.07% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.